Books > Medicine > General issues > History of medicine
|
Buy Now
An Oral History of Neuropsychopharmacology The First Fifty Years Peer Interviews - Volume 1: Starting Up (Paperback)
Loot Price: R578
Discovery Miles 5 780
|
|
An Oral History of Neuropsychopharmacology The First Fifty Years Peer Interviews - Volume 1: Starting Up (Paperback)
(sign in to rate)
Loot Price R578
Discovery Miles 5 780
Expected to ship within 10 - 15 working days
|
THE SERIES The 10 volumes in this series record a fifty year
history of neuropsychopharmacology related by 213 pioneer clinical,
academic, industrial and basic scientists in videotaped interviews,
conducted by 66 colleagues between 1994 and 2008. These volumes
include a preface by the series editor placing its contents in an
historical context and linking each volume to the next. Each volume
is dedicated to a former President of the ACNP and edited by a
distinguished historian or Fellow of the College who provides an
introduction to its themes and a biography of each scientist's
career. The series provides insights into a half century of
discovery and innovation with its rewards and disappointments,
progress and setbacks, including future expectations and hopes for
the field as a whole and the ACNP as an organization. IN THIS
VOLUME Volume I, "Starting Up" is dedicated to Heinz Lehmann,
President, 1965 and edited by Edward Shorter, a distinguished
historian and professor of the history of medicine and psychiatry.
-The 22 pioneers, all men and predominantly Americans, include
trialists, pharmacologists and clinical scientists. From 1952 to
the mid 1960s the earliest clinical trials of the first
psychotropic drugs took place in the V.A., private practice and
State hospitals. -Thousands of people with untreated mental illness
benefited for the first time. Psychoanalysis dominated academia,
the pharmaceutical industry had barely awakened to the potential
for treatment of mental illness and clinical pharmacology was an
infant discipline. But the NIH and NIMH expanded dramatically,
funded by an enthusiastic Congress and the FDA was empowered to
insist on drug efficacy as well as safety. Basic scientists began
to make the first linkages between serendipitous clinical efficacy
and putative neurochemical mechanisms of action.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
You might also like..
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.